Neisseria gonorrhoeae (Ng) is the causative agent of the sexually transmitted infection, gonorrhea. Gonorrhea causes over 100 million new cases worldwide annually and adversely affects the reproductive health of women. Ng has become resistant to almost every antibiotic that has been used and has now achieved superbug status. Vaccines against Ng are urgently needed. Complement (C) is a critical arm of innate immune defenses against Ng. Gonorrhea is characterized by an influx of polymorphonuclear leukocytes (PMNs) into the genital tract, which in concert with Ab and C may facilitate clearance of infection. Vaccine development against Ng has been hindered by lack of knowledge of the correlates of protection. Our vaccine candidate is a peptide mimic (mimitope) of a Ng lipooligosaccharide (LOS) epitope that elicits bactericidal and opsonophagocytic Ab in mice.
In Specific Aim 1, we will elucidate the roles of PMNs, C and C receptors in vaccine Ab efficacy to define the correlates of protection in vivo. Vaccine Ab will be evaluated in mice that lack either PMNs, C3 (opsonin) or C5a (chemotaxin) receptor. Ng binds the C inhibitors, factor H (fH) and C4b- binding protein (C4BP) in a human-specific manner. Binding of human C inhibitors blunts the bactericidal activity of vaccine Ab. We have developed transgenic mice that express both human fH and C4BP, which will be used to evaluate the efficacy of vaccine Ab in vivo and simulate conditions in humans where Ab must surmount human C inhibitors. Ng LOS plays a central role in the pathogenesis of gonorrhea. The ability of Ng to alter its LOS glycan extensions through phase variation contributes to its versatility in immune evasion. We have constructed eight Ng mutants where LOS glycan expression has been 'genotypically fixed'.
In Specific Aim 2 a the ability of each of these mutants to infect mice will be examined, which will elucidate how defined LOS structures driven by fixed genotypes contribute to bacterial fitness in vivo. In light of our data which show that altering LOS glycans modulates the bactericidal activity of vaccine anti-LOS Ab, we will study the efficacy of the vaccine Ab against each 'fit' LOS genotype in Specific Aim 2b. Studies in Aim 2 will correlate LOS geno/phenotypes with fitness and enable us to identify LOS structures that could supplement our current vaccine candidate. Individuals who possess Ab directed against an Ng conserved and ubiquitous outer membrane protein called reduction modifiable protein (Rmp) show impaired bactericidal activity against Ng and are at a higher risk of contracting gonorrhea.
In Specific Aim 3 we will determine the molecular basis whereby Abs directed against Rmp block C-dependent Ab killing of Ng and negatively impact the efficacy of vaccine Ab. Interestingly, anti-Rmp Ab does not block killing of N. meningitidis (Nm). Allelic replacement of rmp across the two species will be performed to define whether subtle sequence differences between Ng and Nm Rmp contribute to differences in blocking across the two pathogens. Corresponding Ng and Nm PorB molecules will also be exchanged across the two species to assess co-dependence of species specific PorB on the blocking effect. Completion of the proposed studies will represent an important step forward in the development of novel vaccines against gonorrhea.

Public Health Relevance

Gonorrhea is a major public health problem worldwide (over 106 million new cases per year) that adversely affects the reproductive health of women. Gonococcal isolates that are resistant to almost every antibiotic in clinical use have heralded an era of untreatable gonorrhea - the CDC has conferred 'superbug' status to Neisseria gonorrhoeae. Vaccines are badly needed for this disease. Using knowledge on how the surface of N. gonorrhoeae changes during infection, we have designed a vaccine candidate to prevent gonorrhea. Studies in this application seek to understand how the vaccine overcomes surface variability and prevents infection in mouse models of gonococcal infection. We aim to define the fundamental host response that eradicates or prevents gonococcal infection in a mouse model of gonorrhea. In addition, we will examine mechanisms of subversion that gonococci use to attempt to overcome vaccine antibodies and prevent them from working.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI114790-03
Application #
9263879
Study Section
Host Interactions with Bacterial Pathogens Study Section (HIBP)
Program Officer
Vincent, Leah Rebecca
Project Start
2015-05-05
Project End
2020-04-30
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Ermert, David; Weckel, Antonin; Magda, Michal et al. (2018) Human IgG Increases Virulence of Streptococcus pyogenes through Complement Evasion. J Immunol 200:3495-3505
Ram, Sanjay; Gulati, Sunita; Lewis, Lisa A et al. (2018) A Novel Sialylation Site on Neisseria gonorrhoeae Lipooligosaccharide Links Heptose II Lactose Expression with Pathogenicity. Infect Immun 86:
Shaughnessy, Jutamas; Lewis, Lisa A; Zheng, Bo et al. (2018) Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae. J Immunol 201:2700-2709
Rice, Peter A; Shafer, William M; Ram, Sanjay et al. (2017) Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development. Annu Rev Microbiol 71:665-686
Ram, Sanjay; Shaughnessy, Jutamas; de Oliveira, Rosane B et al. (2017) Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics. Pathog Dis 75:
Lujan, Eduardo; Partridge, Elizabeth; Giuntini, Serena et al. (2017) Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine. Clin Vaccine Immunol 24:
Blom, Anna M; Magda, Michal; Kohl, Lisa et al. (2017) Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes. J Immunol 199:3828-3839
Wong, Sandy M; Shaughnessy, Jutamas; Ram, Sanjay et al. (2016) Defining the Binding Region in Factor H to Develop a Therapeutic Factor H-Fc Fusion Protein against Non-Typeable Haemophilus influenzae. Front Cell Infect Microbiol 6:40
Shaughnessy, Jutamas; Gulati, Sunita; Agarwal, Sarika et al. (2016) A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol 196:1732-40
Ketterer, Margaret R; Rice, Peter A; Gulati, Sunita et al. (2016) Desialylation of Neisseria gonorrhoeae Lipooligosaccharide by Cervicovaginal Microbiome Sialidases: The Potential for Enhancing Infectivity in Men. J Infect Dis 214:1621-1628

Showing the most recent 10 out of 13 publications